SEC Form 4 · accession 0002097065-26-000005
Legend Biotech Corp · LEGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carlos E Santos
Officer — Chief Financial Officer
Period of report
Sep 21, 2026
Accepted (ET)
Sep 23, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001801198
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Sep 21, 2026 | A | 19,676 | $0.00 | A | 19,676 | D | |
| Ordinary SharesF1,F2,F3 | Sep 21, 2026 | S | 5,430 | $9.14 | D | 14,246 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
- F2Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units.
- F3The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.905 to $9.325 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.